Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on lipoprotein receptor-mediated bacterial lipid clearance and hepatic inflammation in sepsis

FY 2015-16

Summary
Sepsis is a devastating disease that affects millions of people each year, and is fatal in about 30-50% of affected patients. Sepsis results when the immune system overreacts to an infection, resulting in inflammation throughout the entire body (also known as systemic inflammation). Currently, there are no effective treatments for sepsis aside from antibiotics to target the infection and resuscitation fluids to maintain blood pressure. Even if the antibiotics are effective, the immune system does not always stop overreacting and patient outcomes remain poor despite significant improvement. My research is focused on determining the mechanisms by which reducing function of a newly implicated protein in sepsis may be protective. The protein is called PCSK9 and is important in regulating cholesterol and fat (lipid) metabolism in the body. In fact, PCSK9 inhibitors are a newly approved class of drugs for reducing cholesterol levels in the blood to reduce the risk of heart disease. Recent evidence suggests that inhibition or reduced function of PCSK9 can help to increase clearance of bacterial lipids that stimulate the systemic inflammation. However, the mechanism by which this occurs is not clear. Since it is important to understand the mechanism before these drugs can be used to treat sepsis, my research aims to determine exactly how PCSK9 deficiency improves bacterial lipid clearance through the liver and the resulting impact on inflammation. By clarifying the mechanisms involved, we will be one step closer to a potential new treatment for sepsis.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
349908
Name
Grin Peter M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) on lipoprotein receptor-mediated bacterial lipid clearance and hepatic inflammation in sepsis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cecal Ligation And Puncture (Clp); Hepatic Inflammation; Intravital Microscopy; Leukocyte Recruitment; Lipopolysaccharide (Lps); Lipoteichoic Acid (Lta); Low Density Lipoprotein Receptor (Ldlr); Low Density Lipoprotein Receptor-Related Protein 1 (Lrp-1); Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9); Sepsis
Abstract
Sepsis is a devastating disease that affects millions of people each year, and is fatal in about 30-50% of affected patients. Sepsis results when the immune system overreacts to an infection, resulting in inflammation throughout the entire body (also known as systemic inflammation). Currently, there are no effective treatments for sepsis aside from antibiotics to target the infection and resuscitation fluids to maintain blood pressure. Even if the antibiotics are effective, the immune system does not always stop overreacting and patient outcomes remain poor despite significant improvement. My research is focused on determining the mechanisms by which reducing function of a newly implicated protein in sepsis may be protective. The protein is called PCSK9 and is important in regulating cholesterol and fat (lipid) metabolism in the body. In fact, PCSK9 inhibitors are a newly approved class of drugs for reducing cholesterol levels in the blood to reduce the risk of heart disease. Recent evidence suggests that inhibition or reduced function of PCSK9 can help to increase clearance of bacterial lipids that stimulate the systemic inflammation. However, the mechanism by which this occurs is not clear. Since it is important to understand the mechanism before these drugs can be used to treat sepsis, my research aims to determine exactly how PCSK9 deficiency improves bacterial lipid clearance through the liver and the resulting impact on inflammation. By clarifying the mechanisms involved, we will be one step closer to a potential new treatment for sepsis.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Grin, Peter M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~